Adicet Bio

The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.

Adicet Bio announced the first patient dosed in the phase 1/2 trial of ADI-270, an allogeneic gamma delta CAR T cell therapy targeting CD70-positive cancers, for relapsed or refractory clear cell renal cell carcinoma (ccRCC). The FDA granted ADI-270 fast track designation in July 2024. The trial aims to enroll 60 patients with metastatic/advanced ccRCC, with initial data expected in H1 2025. The study evaluates safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity, with completion anticipated by June 2027.

Adicet Bio announced the first patient dosed in a Phase 1 trial of ADI-270 for metastatic/advanced clear cell renal cell carcinoma (ccRCC), with preliminary data expected in H1 2025. ADI-270 is an allogeneic gamma delta CAR T cell therapy targeting CD70-positive cancers, designed to improve clinical responses in RCC patients.

Adicet Bio appoints Dr. Julie Maltzman as Chief Medical Officer to lead clinical development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. With over 20 years of experience, Dr. Maltzman's expertise in drug development from research to commercialization is expected to advance Adicet's pipeline.

Adicet Bio announced the first lupus nephritis patient dosed with ADI-001, an allogeneic gamma delta CAR T cell therapy targeting B cells, in a phase 1 study across four autoimmune disease groups. Preliminary data expected in 2025.

DelveInsight's report highlights a robust lupus nephritis pipeline with 30+ companies developing 35+ therapies, including key players like AstraZeneca and Novartis. Promising therapies like Anifrolumab and Ianalumab are in various clinical phases, with recent updates from companies like Adicet Bio and Kyverna Therapeutics. The report provides comprehensive insights into the pipeline, therapeutic assessments, and market dynamics.

Adicet Bio, Inc. granted an inducement award on November 29, 2024, to a new hire, providing non-qualified stock options for 6,000 shares at $1.13 per share, vesting over four years. The award was authorized under the 2022 Inducement Plan, amended in 2023, and complies with Nasdaq Listing Rule 5635(c)(4).

DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.